Sema4 and CM Life Sciences have entered into a definitive business combination agreement. Upon closing, CM Life Sciences will be renamed and its common stock will be listed on the Nasdaq Global Market under a name and a ticker symbol to be announced at a later date.
“This transaction is a significant milestone for Sema4,” said Eric Schadt, Ph.D., Founder and CEO of Sema4. “The additional resources will allow us to greatly accelerate our business plans organically and inorganically, developing and bringing in more cutting-edge precision model solutions across multiple disease areas.”
Separately, Sema4 has appointed Isaac Ro Chief Financial Officer … more